Fast and cost-effective SARS-CoV-2 variant detection using Oxford Nanopore full-length spike gene sequencing.

Oxford Nanopore Technologies SARS-CoV-2 spike gene surveillance

Journal

Microbial genomics
ISSN: 2057-5858
Titre abrégé: Microb Genom
Pays: England
ID NLM: 101671820

Informations de publication

Date de publication:
05 2023
Historique:
medline: 22 5 2023
pubmed: 18 5 2023
entrez: 18 5 2023
Statut: ppublish

Résumé

Most biologically relevant and diagnostic mutations in the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) genome have been identified in the S gene through global genomic surveillance efforts. However, large-scale whole-genome sequencing (WGS) is still challenging in developing countries due to higher costs, reagent delays and limited infrastructure. Consequently, only a small fraction of SARS-CoV-2 samples are characterized through WGS in these regions. Here, we present a complete workflow consisting of a fast library preparation protocol based on tiled amplification of the S gene, followed by a PCR barcoding step and sequencing using Nanopore platforms. This protocol facilitates fast and cost-effective identification of main variants of concern and mutational surveillance of the S gene. By applying this protocol, report time and overall costs for SARS-CoV-2 variant detection could be reduced, contributing to improved genomic surveillance programmes, particularly in low-income regions.

Identifiants

pubmed: 37200071
doi: 10.1099/mgen.0.001013
pmc: PMC10272875
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Nat Commun. 2022 Nov 16;13(1):7003
pubmed: 36385137
Bioinformatics. 2014 Nov 15;30(22):3276-8
pubmed: 25095880
Nature. 2021 May;593(7858):176-177
pubmed: 33953391
Infect Genet Evol. 2021 Aug;92:104910
pubmed: 33975021
Front Med (Lausanne). 2022 Jan 11;8:798130
pubmed: 35087848
Virus Evol. 2021 Jul 30;7(2):veab064
pubmed: 34527285
Biotechniques. 2002 Dec;33(6):1210-2, 1214
pubmed: 12503300
J Virol Methods. 2022 Jun;304:114512
pubmed: 35257682
PLoS One. 2021 Dec 14;16(12):e0260850
pubmed: 34905589
Microb Genom. 2020 Mar;6(3):
pubmed: 32065578
J Virol Methods. 2023 Feb;312:114648
pubmed: 36368344
Signal Transduct Target Ther. 2022 Apr 26;7(1):138
pubmed: 35474215
Appl Transl Genom. 2016 Mar 10;9:15-9
pubmed: 27354935
Front Genet. 2021 Jul 28;12:711437
pubmed: 34394197
Biol Methods Protoc. 2020 Jul 18;5(1):bpaa014
pubmed: 33029559
Nat Rev Genet. 2022 Sep;23(9):547-562
pubmed: 35459859
Nat Protoc. 2017 Jun;12(6):1261-1276
pubmed: 28538739
Gigascience. 2021 Feb 16;10(2):
pubmed: 33590861
Nat Microbiol. 2022 Aug;7(8):1161-1179
pubmed: 35798890
Emerg Infect Dis. 2021 Nov;27(11):2957-2960
pubmed: 34437831
Influenza Other Respir Viruses. 2021 Nov;15(6):707-710
pubmed: 34346163
Euro Surveill. 2017 Mar 30;22(13):
pubmed: 28382917
Nat Microbiol. 2021 Jul;6(7):821-823
pubmed: 34108654
Euro Surveill. 2020 Aug;25(32):
pubmed: 32794443
Rand Health Q. 2022 Aug 31;9(4):24
pubmed: 36238008
Sci Rep. 2022 Feb 14;12(1):2419
pubmed: 35165301
Sci Rep. 2021 Aug 5;11(1):15869
pubmed: 34354202
PLoS One. 2022 Jan 20;17(1):e0262170
pubmed: 35051202
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681
Brief Bioinform. 2021 Mar 22;22(2):616-630
pubmed: 33279989
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
BMC Genomics. 2022 Feb 11;23(1):121
pubmed: 35148677

Auteurs

Cecilia Salazar (C)

Laboratorio de Genómica Microbiana, Institut Pasteur de Montevideo, Montevideo, Uruguay.
Centro de Innovación en Vigilancia Epidemiológica, Institut Pasteur de Montevideo, Montevideo, Uruguay.

Ignacio Ferrés (I)

Laboratorio de Genómica Microbiana, Institut Pasteur de Montevideo, Montevideo, Uruguay.
Centro de Innovación en Vigilancia Epidemiológica, Institut Pasteur de Montevideo, Montevideo, Uruguay.

Mercedes Paz (M)

Centro de Innovación en Vigilancia Epidemiológica, Institut Pasteur de Montevideo, Montevideo, Uruguay.
Laboratorio de Evolución Experimental de Virus, Institut Pasteur de Montevideo, Montevideo, Uruguay.
Laboratorio de Virología Molecular, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay.

Alicia Costábile (A)

Centro de Innovación en Vigilancia Epidemiológica, Institut Pasteur de Montevideo, Montevideo, Uruguay.
Laboratorio de Evolución Experimental de Virus, Institut Pasteur de Montevideo, Montevideo, Uruguay.
Laboratorio de Virología Molecular, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay.
Sección Bioquímica, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay.

Gonzalo Moratorio (G)

Centro de Innovación en Vigilancia Epidemiológica, Institut Pasteur de Montevideo, Montevideo, Uruguay.
Laboratorio de Evolución Experimental de Virus, Institut Pasteur de Montevideo, Montevideo, Uruguay.
Laboratorio de Virología Molecular, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay.

Pilar Moreno (P)

Centro de Innovación en Vigilancia Epidemiológica, Institut Pasteur de Montevideo, Montevideo, Uruguay.
Laboratorio de Evolución Experimental de Virus, Institut Pasteur de Montevideo, Montevideo, Uruguay.
Laboratorio de Virología Molecular, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay.

Gregorio Iraola (G)

Laboratorio de Genómica Microbiana, Institut Pasteur de Montevideo, Montevideo, Uruguay.
Centro de Innovación en Vigilancia Epidemiológica, Institut Pasteur de Montevideo, Montevideo, Uruguay.
Wellcome Sanger Institute, Hinxton, UK.
Centro de Biología Integrativa, Universidad Mayor, Santiago de Chile, Chile.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH